CWRU startup NervGen Pharma raises $7.5 million from initial public offering

NervGen Pharma Corp., a Vancouver-headquartered company founded to develop regenerative-medicine technology licensed from Case Western Reserve University, has raised about $7.5 million from an initial public offering.

On Friday, March 15, Shares of NervGen are to begin trading on the Canadian TSX Venture Exchange under the symbol “NGEN,” according to a news release.

Dedicated to creating innovative solutions to treat nerve damage, the two-year-old company issued 10 million common shares at $1 per share (Canadian dollars) on March 13. Proceeds will be used to advance the company’s leading product, NVG-291, toward clinical development to treat spinal cords, according to the release.

Click here to read the complete article.

Story excerpt provided by Crain’s Cleveland Business.

Originally published March 15, 2019.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: